MHMichael W. Holliday

Michael W. Holliday

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael W. Holliday has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Insights and Future Directions on the Role of GLP-1 Receptor Agonists in Chronic Kidney Disease

    by Kavya Rajan, Arjun Krishen Jutley, Michael W Holliday Jr, Sankar D Navaneethan

    Chronic kidney disease (CKD) incidence continues to rise along with obesity and diabetes, driving substantial medical, psychosocial, and economic burdens for patients. Beyond glycemic control and the recommended therapies of ACEI/ARB, SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a cornerstone therapy to benefit mortality, heart and kidney outcomes. The following review will discuss recent advances to our understanding of the kidney benefits of GLP1 agonism in high-risk populations, including patients with type 2 diabetes mellitus, obesity, those with established cardiovascular disease. Renal signals from cardiovascular outcomes trials disclosed less albuminuria and slower estimated glomerular filtration rate (eGFR) decline with GLP1RA therapy, often additive to sodium–glucose cotransporter-2 inhibition. Dedicated kidney studies now show semaglutide slows CKD progression and lowers mortality in diabetics with CKD, underscoring the relevance of new guidelines that recommend GLP1RA therapy for specific populations. Future priorities should include trials of GLP-1RA in non-diabetic patients with CKD, as well as further evaluation of dual or triple agonists (GLP-1/GIP/glucagon) and clarification of oral GLP1RA efficacy. Overall, GLP-1–based therapies represent a transformative strategy to improve weight, cardiovascular health, and kidney outcomes in diabetic CKD patients.

  • Chronic Interstitial Nephritis in Agricultural Communities

    by Michael W. Holliday, Ravikumar Nagavenkata Majeti, David Sheikh-Hamad

    Chronic interstitial nephritis in agricultural communities (CINAC) is an epidemic of kidney disease affecting specific tropical and subtropical regions worldwide and is characterized by progressive CKD in the absence of traditional risk factors, such as hypertension and diabetes. CINAC prevalence is higher among young, male agricultural workers, but it also affects women, children, and nonagricultural workers in affected areas. Biopsies from patients with CINAC across regions commonly demonstrate tubular injury with lysosomal aggregates, tubulointerstitial inflammation, and fibrosis and variable glomerular changes. Each endemic area holds environmental risk factors and patient/genetic milieus, resulting in uncertainty about the cause(s) of the disease. Currently, there is no specific treatment available for CINAC. We highlight survey findings of Houston-based migrant workers with CINAC and draw similarities between kidney injury phenotype of patients with CINAC and mice treated chronically with paraquat, an herbicide used worldwide. We propose potential pathways and mechanisms for kidney injury in patients with CINAC, which may offer clues for potential therapies.


  • Open Access

    C22:0- and C24:0-dihydroceramides Confer Mixed Cytotoxicity in T-Cell Acute Lymphoblastic Leukemia Cell Lines

    by Michael W. Holliday Jr., Stephen B. Cox, Min H. Kang, Barry J. Maurer

    We previously reported that fenretinide (4-HPR) was cytotoxic to acute lymphoblastic leukemia (ALL) cell lines in vitro in association with increased levels of de novo synthesized dihydroceramides, the immediate precursors of ceramides. However, the cytotoxic potentials of native dihydroceramides have not been defined. Therefore, we determined the cytotoxic effects of increasing dihydroceramide levels via de novo synthesis in T-cell ALL cell lines and whether such cytotoxicity was dependent on an absolute increase in total dihydroceramide mass versus an increase of certain specific dihydroceramides. A novel method employing supplementation of individual fatty acids, sphinganine, and the dihydroceramide desaturase-1 (DES) inhibitor, GT-11, was used to increase de novo dihydroceramide synthesis and absolute levels of specific dihydroceramides and ceramides. Sphingolipidomic analyses of four T-cell ALL cell lines revealed strong positive correlations between cytotoxicity and levels of C22:0-dihydroceramide (ρ = 0.74–0.81, P ≤ 0.04) and C24:0-dihydroceramide (ρ = 0.84–0.90, P ≤ 0.004), but not between total or other individual dihydroceramides, ceramides, or sphingoid bases or phosphorylated derivatives. Selective increase of C22:0- and C24:0-dihydroceramide increased level and flux of autophagy marker, LC3B-II, and increased DNA fragmentation (TUNEL assay) in the absence of an increase of reactive oxygen species; pan-caspase inhibition blocked DNA fragmentation but not cell death. C22:0-fatty acid supplemented to 4-HPR treated cells further increased C22:0-dihydroceramide levels (P ≤ 0.001) and cytotoxicity (P ≤ 0.001). These data demonstrate that increases of specific dihydroceramides are cytotoxic to T-cell ALL cells by a caspase-independent, mixed cell death mechanism associated with increased autophagy and suggest that dihydroceramides may contribute to 4-HPR-induced cytotoxicity. The targeted increase of specific acyl chain dihydroceramides may constitute a novel anticancer approach.


  • Abstract 4661: Levels of C22:0- and C24:0-dihydroceramide correlate with cytotoxicity in T-cell acute lymphoblastic leukemia cell lines

    by Michael W. Holliday, Steven B. Cox, Min H. Kang, Barry J. Maurer

    Fenretinide (4-HPR) is a synthetic retinoid that is cytotoxic to several T-cell acute lymphoblastic leukemia (ALL) cell lines, and has demonstrated activity in a variety of cancer cell lines in vitro. Reported mechanisms of action for fenretinide include both increased reactive oxygen species (ROS) generation in some cell lines and increased dihydroceramide levels. Dihydroceramides are the product of N-acylation of sphinganine with fatty acid chains varying in carbon length and degree of saturation. Although synthetic, short-acyl chain dihydroceramides have been reported to be non-cytotoxic in cell culture in vitro, the cytotoxic potencies of native-acyl chain dihydroceramides are unknown. In the current study, increased synthesis of specific native-acyl chain dihydroceramides was targeted through a novel cell culture method employing concurrent exogenous administration of sphinganine, GT-11, a dihydroceramide desaturase inhibitor, and specific individual fatty acids. Sphingolipids were analyzed using LC/MS/MS. Cytotoxicity was measured using the fluorescence-based cytotoxicity assay DIMSCAN. Non-parametric correlation analysis of cytotoxicity and absolute sphingolipid levels revealed a strong positive correlation between cytotoxicity and C22:0-dihydroceramide (α = 0.75, P < 0.001) and C24:0-dihydroceramide (α = 0.84, P < 0.001) in the CCRF-CEM ALL cell line, with similar results observed independently in MOLT-4, COG-LL-317 and COG-LL-332 ALL cell lines. Additionally, fenretinide cytotoxicity was significantly increased by co-treatment with C22:0-fatty acid in association with an increase of C22:0- and C24:0-dihydroceramides. These findings suggest that the addition of specific fatty acids, perhaps in a tumor-type specific manner, through simple dietary or intravenous supplementation, or via concurrent incorporation into drug delivery vehicles, may improve the clinical efficacy of dihydroceramide-increasing anticancer agents, such as fenretinide. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4661. doi:1538-7445.AM2012-4661